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Objective. To investigate the prevalence of p16INK4 a, p14ARF, tumor protein p53 (TP53), and human telomerase reverse tran-
scriptase (hTERT) promoter hypermethylation in mucoepidermoid carcinomas (MECs) and search for a possible association between
methylation status and clinicopathological parameters.
Study design. DNA extracted from 35 formalin-fixed and paraffin-embedded MEC samples and 10 normal salivary gland (NSG)
tissue samples was analyzed for the presence of promoter hypermethylation using methylation-specific polymerase chain reac-
tion testing.
Results. The percentages of gene hypermethylation in MECs versus NSGs were the following: p14: 100% versus 20% (P < .001);
p16: 60% versus 20% (P = .035); hTERT: 54.3% versus 20% (P = .078); and TP53: 31.4% versus 30% (P = .981). Multiple sites
were found to be methylated in 86% of MECs compared with 10% in NSGs (P < .001). TP53 and hTERT were more often meth-
ylated in lower clinical stages (P = .033 and P = .005, respectively).
Conclusions. Hypermethylation of p14 appears to be an important event in the development of mucoepidermoid carcinoma.
High frequency of gene hypermethylation and high incidence of methylation at multiple sites point to the importance of epi-
genetic phenomena in the pathogenesis of MECs, although with modest impact on clinical parameters. (Oral Surg Oral Med
Oral Pathol Oral Radiol 2018;125:52–58)
Mucoepidermoid carcinoma (MEC) accounts for ap-
proximately 35% of salivary gland cancers, ranging from
nonaggressive low-grade to aggressive high-grade
tumors.1-5 Several malignant and benign tumors can his-
tologically mimic MEC, such as Warthin tumor, adenoid
cystic carcinoma, and squamous cell carcinoma, among
others, leading to misdiagnosis.6,7 MEC pathogenesis
studies have mainly been focused on the reciprocal chro-
mosomal translocation t(11;19)(q21;p13), which gives rise
to a fusion oncoprotein MECT1-MAML2. This fusion
appears to be one of the drivers of MEC development
through Notch signaling disruption.8 It also represents
an important prognostic parameter9,10; namely, it was found
that patients with MEC harboring the translocation have
a less aggressive form of tumor and a more favorable
outcome.11,12 Recently, using whole exome sequencing,
several new alterations have been found in MECs, such
as tumor protein p53 (TP53) and POU6F2 mutations.9
Still, these genetic changes cannot explain all MEC cases.
The latest molecular studies have broadened the knowl-
edge on the importance of epigenetic changes associated
with salivary gland cancer (SGC) development, in par-
ticular DNA methylation, as a mechanism of gene
silencing. Kishi et al.13 found, for instance, that RB1 was
hypermethylated in 42% of cases of SGC, and Nikolic
et al.14 reported that approximately 70% of pleomor-
phic adenomas harbored hypermethylated p14 and p16.
Using a microarray approach, Bell et al.15 also found
several highly methylated genes in adenoid cystic car-
cinoma. Williams et al.16 found 48% of methylated
RASSF1A in salivary duct cancers, whereas Zhang et al.17
correlated RASSF1A promoter hypermethylation with
poor survival in patients with salivary adenoid cystic car-
cinoma in a Chinese population. In the same type of
tumors, on the other hand, Tan et al.18 found that AQP1
was hypomethylated in 75% of cases.
Nonetheless, the number of published studies is still
relatively limited and mostly focused on gene methyla-
tion in adenoid cystic carcinomas. Findings on DNA
methylation status in mucoepidermoid carcinomas are
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Statement of Clinical Relevance
Methylation of the p14 tumor suppressor gene seems
to be a critical event in the pathogenesis of mucoepi-
dermoid carcinoma and consequently p14 could be
potentially used as a target in novel therapeutic ap-
proaches based on DNA epigenetic modifications.
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extremely scarce,13,19 and that fact prompted us to explore
the potential role of methylation in the pathogenesis of
this type of tumor. The following genes known to be im-
plicated in the etiology of different malignancies were
selected for the present study: CDKN2A or INK4 a-ARF
locus, which encodes 2 tumor suppressors (p16INK4 a and
p14ARF), TP53, and human telomerase reverse tran-
scriptase (hTERT). p16 is a potent cell cycle regulator,
and when absent or nonfunctional, the progression of the
cell cycle into the S phase is enabled.20 p14 is one of the
key p53 regulators; thus methylated p14 would mean in-
active p53 tumor suppressor.21 The TP53 gene, the most
commonly mutated gene in human cancer, encodes the
p53 suppressor, which promotes cell cycle arrest or apop-
tosis under replication stress; epigenetic modifications
affect TP53 expression and p53 function.22 The hTERT
gene encodes the protein subunit of the enzyme
telomerase. Telomere maintenance by telomerase has a
key role in carcinogenesis, and hTERT expression is
known to be the limiting step in telomerase function.23
With the aim of assessing their respective contribu-
tion to MEC development, progression, and outcome, the
methylation status of 2 gene promoters analyzed in the
past (p14 and p16) and 2 gene promoters not examined
before (TP53 and hTERT) has been determined.
MATERIALS AND METHODS
This retrospective study included 45 formalin-fixed,
paraffin-embedded samples originating from 35 pa-
tients with mucoepidermoid carcinoma (surgically treated
between 2000 and 2010 at the Clinic for Maxillofacial
Surgery, School of Dental Medicine, University of Bel-
grade) and 10 controls. The control specimens were
normal salivary glands (NSGs) obtained from patients
with oral cancer who underwent radical neck dissec-
tion, which included the submandibular glands. Only
tissue histopathologically confirmed as tumor free was
used as control tissue. Initial histopathologic findings ob-
tained from the Department of Pathology, School of
Dental Medicine, University of Belgrade, were con-
firmed at the Institute of Hematopathology Hamburg,
Hamburg, Germany. Patients with MEC with distant me-
tastases were excluded from the study. MECT1-MAML2
translocation analysis on these cases was done in a pre-
vious study.11 Relevant clinicopathologic data are given
in Table I. The research was conducted in full accor-
dance with the World Medical Association Declaration
of Helsinki (Version 2002).
The promoter methylation status was determined by
methylation-specific polymerase chain reaction (PCR).
An adaptation of the protocol suggested by Herman et al.24
was implemented. Genomic DNA was extracted from
formalin-fixed, paraffin-embedded samples using phenol-
chloroform extraction and was modified by sodium
bisulfite treatment with an EZ-DNA Methylation Kit,
according to manufacturer’s recommendations (Zymo Re-
search, Orange, CA, USA). Modified DNA was purified
and resuspended in 20 µL of elution buffer provided in
the kit. Subsequent methylation-specific PCR was used
to distinguish unmethylated alleles, based on DNA se-
quence alterations after bisulfite treatment of DNA. Two
separate PCR reactions were performed for each gene,
using primers designed for methylated and unmethylated
CpG islands in the promoter region. Primers used in this
study were reported previously24-27 and the sequences are
listed in Table II. The modified genomic DNA samples
were PCR amplified in a total volume of 50 µL, and the
reaction mix contained 1 × PCR buffer (10 mM Tris-
hydrochloride, 50 mM potassium chloride, 0.1% Triton
X-100), 8 mM magnesium chloride, 1.25 mM
deoxynucleoside triphosphates, 0.6 µM primers
(Invitrogen, Life Technologies, Carlsbad, CA, USA),
0.4 µg/µL bovine serum albumin, 5% dimethyl sulfox-
ide, 1.5 U Taq polymerase (Thermo Scientific, Hudson,
NH, USA), and 3 µL of bisulfite-treated DNA tem-
plate. Amplification was performed in a PeqStar 96
Universal thermal cycler (PEQLAB Biotechnologie
GmbH, Erlangen, Germany) under the following con-
ditions: initial denaturation at 95°C for 5 min, followed
by 40 cycles 95°C denaturation for 30 s, annealing for
30 s (primer-specific temperatures are listed in Table 2),
72°C extensions for 30 s, and final extension at 72°C for
4 min. Genomic DNA extracted from lymphocytes of
healthy donors was used as control for unmethylated
genes. The same DNA, treated in vitro with Spiroplasma
sp. strain MQ1 (SssI) methyltransferase, was used as a
positive control for methylated genes. PCR products were
loaded on 8% polyacrylamide gels, stained with eth-
idium bromide, and visualized under ultraviolet light.
Table I. Clinicopathologic features of patients with
mucoepidermoid carcinoma (MEC) and demographic
data for patients with MEC and normal salivary glands
(NSG)
Characteristic MECs NSGs
Mean age, y 53.03 ± 17.53 56.27 ± 12.05
Male:female ratio 0.9:1 1.4:1
Mean duration of
disease, y
4.47 ± 3.57
Tumor site Parotid 18
Submandibular 6
Sublingual 4
Palate 5
Retromolar 2
Tumor size >2 cm 15
<2 cm 20
Positive lymph
nodes
10
Clinical stage I and II 25
III and IV 10
Perineural
invasion
10
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The genes were considered as (1) nonmethylated, when
only the reactions with the unmethylated target-specific
(U) primers had amplification, and (2) methylated or par-
tially methylated, when a positive amplification was
obtained only with the methylated target-specific (M)
primer pair or with both (U and M). Reamplification of
20% of randomly chosen samples was done to confirm
the findings, and there were no discrepancies between
methylation statuses determined in duplicate.
Statistical analysis
All statistical analyses were done using Statistical Package
for Social Science (SPSS software package, Version 17.0;
SPSS Inc., Chicago, IL, USA). The differences of gene
methylation status between different tumor types were
assessed using Pearson’s χ2 test unless the smallest ex-
pected value was <5, in which case Fisher’s exact test
was used. P value < .05 was considered statistically
significant.
RESULTS
Methylation status
The most remarkable finding was that 100% of MECs
exhibited p14 promoter hypermethylation, versus
only 20% of control specimens (P < .001). p16
hypermethylation was also statistically more common in
MECs than in controls (60% vs. 20%, P = .035). No sta-
tistically significant difference was identified for the
presence of TP53 hypermethylation between MECs and
NSGs (31.4% vs. 30%, P = .931), or for the presence of
hTERT hypermethylation (54.3% vs. 20%, P = .078). The
frequencies of methylated promoter regions are summa-
rized in Table III.
In all 35 analyzed cancer cases at least 1 of the 4 ex-
amined promoters had hypermethylation. A total of 30
(86%) MECs exhibited simultaneous hypermethylation
of 2 or more genes, versus only 1 control sample (10%)
with more than 1 methylated gene (P < .001) (Table IV).
Methylation status and clinical stage/histologic
grade
All MEC cases harboring TP53 hypermethylation had
been classified as lower clinical stages (P = .033). Sim-
ilarly, hTERT hypermethylation dominated in stages I and
II compared with stages III and IV (P = .002). There was
no association between methylation and histologic grades
(Table V).
Methylation status and overall survival
Promoter methylation status did not have a statistically
significant association with survival rates, although pa-
tients with methylated p16 promoter appeared to have
Table II. Primer sequences, product lengths, and annealing temperatures
Primer Primer sequence Length (bp) Annealing temperature
p14ARF U1 TTTTTGGTGTTAAAGGGTGGTGTAGT
p14ARF U2 CACAAAAACCCTCACTCACAACAA 132 53°C
p14ARF M1 GTGTTAAAGGGCGGCGTAGC
p14ARF M2 AAAACCCTCACTCGCGACGA 122 53°C
p16INK4 a U1 TTATTAGAGGGTGGGGTGGATTGT
p16INK4 a U2 CAACCCCAAACCACAACCATAA 151 60°C
p16INK4 a M1 TTATTAGAGGGTGGGGCGGATCGC
p16INK4 a M2 GACCCCGAACCGCGACCGTAA 150 65°C
TP53 U1 TTGGTAGGTGGATTATTTGTTT
TP53 U2 CCAATCCAAAAAAACATATCAC 247 58°C
TP53 M1 TTCGGTAGGCGGATTATTTG
TP53 M2 AAATATCCCCGAAACCCAAC 193 58°C
hTERT U1 TTGAGAATTTGTAAAGAGAAATGATG
hTERT U2 ACTAAAAACAAACCCAAAAACACA 133 55°C
hTERT M1 TTGAGAATTTGTAAAGAGAAATGAC
hTERT M2 TAAAAACGAACCCGAAAACG 131 55°C
bp, base pair; hTERT, human telomerase reverse transcriptase; M, methylated sequence; TP53, tumor protein p53; U, unmethylated sequence.
Table III. Distribution of methylated gene promoters in mucoepidermoid carcinoma (MEC) and normal salivary
gland (NSG) groups
p16 (%) p14 (%) TP53 (%) hTERT (%)
No. of cases (%) MEC 35 (100) 21 (60) 35 (100) 11 (31.4) 19 (54.3)
NSG 10 (100) 2 (20) 2 (20) 3 (30) 2 (20)
χ2 (Fisher’s exact) P value .035* <.001* .931 .078
hTERT, human telomerase reverse transcriptase; TP53, tumor protein p53.
*Statistically significant.
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poorer survival than those with unmethylated p16. On
the contrary, patients with methylated TP53 and hTERT
promoter had a trend of better overall survival com-
pared with patients with unmethylated TP53 and hTERT
(P = .120 and P = .151, respectively) (Figure 1).
Methylation status and MECT1-MAML2 fusion
No correlation was found between the presence of the
translocation and methylation of either of the genes
(P = .778, P = .197, and P = .778 for p16, hTERT, and
TP53, respectively).
DISCUSSION
DNA methylation, an important mechanism of gene ex-
pression regulation, is known to be involved in tumor
development and progression. Indeed, it was suggested
that hypermethylation is one of the main mechanisms of
tumor suppressor gene (TSG) inactivation.28
Our results indicate that silencing of p14ARF, a crucial
regulator of p53 activity, might be a significant event in
MEC pathogenesis because this TSG was methylated in
all 35 tumor samples. Although only qualitative analy-
sis of methylation was performed, the fact that 100% of
cases harbored this epimutation points to its relevance.
With either hypermethylated or in any other way inac-
tivated p14, the cell will not be able to correct damages,
even with intact (wild type) p53. The present study on
the importance of p14 epigenetic inactivation in the patho-
genesis of MECs is in agreement with our previous
findings on pleomorphic adenoma and carcinoma ex pleo-
morphic adenoma.14 Such a high frequency of methylation
is not an uncommon phenomenon. For instance, the E
cadherin gene was found to be hypermethylated in 95%
of cutaneous squamous cell carcinomas.29 It must be
emphasized that only 1 study was previously published
on p14 methylation in mucoepidermoid cancer. Nishimine
et al.30 analyzed 7 cases of MEC for the presence of p14
gene alterations and found 1 deletion and no methyla-
tion at all. When considering their entire SGC sample,
in which adenoid cystic carcinomas dominated, 19.4%
of methylated p14 promoter was found.30 Quite low rates
for p14 methylation were found by Weber et al. (2.5%)31
in pleomorphic adenomas. Ishida et al.32 reported p14 pro-
moter hypermethylation in 20% of oral squamous cell
carcinomas but found a significant association with later
clinical stages and suggested that it could be a key mo-
lecular event in tumor progression.
The p16INK4 a tumor suppressor gene encodes a cyclin-
dependent kinase inhibitor with an important role in the
cell-cycle regulation at the G1/S phase checkpoint. The
absence of functional p16 protein leads to aberrant cell-
cycle control and promotes cancer cell proliferation.
In the present study, 60% of MEC cases had p16
hypermethylation, which is fairly in line with some pre-
vious findings on the importance of this epigenetic event
in salivary gland carcinogenesis, with frequencies varying
between 29% and 47%.19,31,33 Only 2 papers analyzed p16
methylation in MECs—Guo et al.19 reported 34% of meth-
ylated samples, whereas Nishimine et al.30 did not find
any methylated p16 promoter in MECs. In accordance
with our findings, Guo et al.19 indicated that the meth-
ylation rate of p16 in MECs increases with progression
of tumor stage, but without statistical significance. Al-
though their frequencies of p14 and p16 methylation were
lower than ours (19% and 32%, respectively), Weber
et al.,34 however, concluded that the disruption of the
INK4a-ARF/p53 pathway, by different mechanisms, was
a very common event (84%) in head and neck cancer
squamous cell carcinomas.
Table IV. Methylation on multiple sites in mucoepidermoid carcinomas (MEC) and normal salivary glands
1 Methylation (%) 2 Methylations (%) 3 Methylations (%) 4 Methylations (%) No methylations (%) P
MECs 5 (14.3) 13 (37.1) 13 (37.1) 4 (11.4) 0 (0)
NSGs 7 (70) 1 (10) 0 (0) 0 (0) 2 (20) <.001*
*Statistically significant.
Table V. Distribution of methylated gene promoters in mucoepidermoid carcinomas in relation to histologic grade
and clinical stage
Histologic grade Clinical stage
1 (%) 2 (%) 3 (%) P 1&2 (%) 3&4 (%) P
N 12 (100) 11 (100) 12 (100) 26 (100) 9 (100)
p16 6 (50) 7 (64) 8 (67) .676 15 (58) 6 (67) .712
p14 12 (100) 11 (100) 12 (100) 26 (100) 9 (100)
TP53 6 (50) 4 (36) 1 (8) .081 11 (42) 0 (0) .033*
hTERT 7 (58) 8 (73) 4 (33) .156 18 (69) 1 (11) .005*
hTERT, human telomerase reverse transcriptase; N, number of patients per histologic grade or clinical stage; TP53, tumor protein p53.
*Statistically significant.
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The conflicting findings related to p14 and p16 meth-
ylation frequencies may be due to different factors, such
as gender, diet, stress, environment, and so on.35-37 Eth-
nicity is also known to greatly affect DNA methylation
patterns38,39 (and consequently gene expression). Finally,
the use of detection assays with different sensitivity might
in part explain the differences between the results.
Altered TP53 methylation patterns have been associ-
ated with multiple malignancies, including oral cancer.40
According to the present study, hypermethylation of TP53
is not a common event in salivary gland malignancies,
and this could be a logical finding in line with high
frequency of p14 methylation. Namely, infrequent meth-
ylation of TP53 does not exclude p53 from the pathogenic
process but rather supports the hypothesis that p53 in-
activation is preferentially achieved via p14 silencing.
Some studies have found TP53 methylation in cancer
tissues,41 whereas others state that TP53 hypermethylation
could be a normal event in healthy cells,40 which is also
in agreement with our results.
One of the most important regulatory mechanisms of
hTERT gene activity, and therefore of telomerase activ-
ity, is considered to be its promoter methylation, although
sometimes in contrast to the general model of DNA meth-
ylation as a gene-silencing mechanism.42 Renaud et al.43
have proposed that the purpose of CpG island methyla-
tion in hTERT promoter is to prevent the binding of
hTERT inhibitors and to allow transcription. In the present
study, a statistically higher frequency of hTERT
hypermethylation was found in tumors than in con-
trols, suggesting that this molecular event might also
play a role in the development of MECs. This is in ac-
cordance with some other studies that reported
hypermethylation in cancerous tissue but not in normal
tissue.44,45 The association of hTERT methylation with
lower histologic grades and clinical stages would imply
its role in the earlier phases of tumorigenesis. It also might
suggest the existence of a molecular subtype of low-
grade MECs with methylated hTERT and good survival.
Generally in the present study none of the methyla-
tion events had significant association with patients’
survival, which is not an infrequent situation. Although
p16 methylation has been associated with poorer sur-
vival in head and neck cancer,46 results similar to
ours regarding the lack of relevance of p16 and/or p14
methylation on survival have been found in oral,
oropharyngeal,47 and head and neck squamous
carcinomas.48
Neoplastic cells often exhibit aberrant methylation pro-
files of genes involved in cell-cycle regulation, DNA
repair, and/or angiogenesis.28 A so-called CpG island
methylator phenotype was proposed by Toyota et al.49
The authors categorized all cancers into those with
genome-wide methylation and those with rare methyla-
tion events. The former are more at risk of transcriptionalFi
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silencing of numerous TSGs by promoter methylation.49
In the present study, we found that 2 or more genes were
simultaneously hypermethylated in 86% of cases, which
implies that hypermethylation at multiple sites might be
very important in salivary gland carcinogenesis.
CONCLUSIONS
Hypermethylation of p14 appears to be a critical event
in the development of mucoepidermoid carcinomas. Al-
though in general no important association was found with
clinical features, high frequency of hypermethylation of
3 of 4 studied gene promoters points to the importance
of epigenetic phenomena in the pathogenesis of sali-
vary gland neoplasms.
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